Magnesium Research
April 1, 2018
Natalia Górska, Wiesław Jerzy Cubała, Jakub Słupski et al.
8 citations
Depression is a leading cause of disability, and many adults with major depression do not achieve remission with first-line treatments. Magnesium influences several neurotransmitter systems involved in emotional processes, including serotonergic, noradrenergic, dopaminergic, GABAergic, and glutamatergic systems. The mechanism of antidepressants' action involves the glutamatergic system, and magnesium ions may play a role in major depressive disorder pathophysiology by blocking the N-methyl-D-aspartate receptor (NMDAR). Ketamine, an NMDAR antagonist, has fast-acting antidepressant and antisuicidal effects. The evidence discussed suggests a possible synergistic interaction between magnesium and ketamine's pharmacodynamic activity in mood disorders.
Brain Sciences
December 11, 2020
Jakub Słupski, Wiesław Jerzy Cubała, Natalia Górska et al.
7 citations
Serum copper concentration changes during ketamine treatment in patients with treatment-resistant depression, but no clear link between copper levels and treatment response was found. Patients with major depressive or bipolar disorder received weekly ketamine infusions, and copper levels were measured before, during, and after treatment. Copper concentration was significantly higher before treatment than after the fifth infusion, and also higher after the full course than after the fifth infusion. However, changes in copper levels did not correlate with scores on depression or mania rating scales, nor with somatic comorbidities. The findings provide data on copper's role in short-term ketamine therapy but do not support copper as a marker of treatment response.
Frontiers in Psychiatry
December 2, 2021
Maria Gałuszko‐węgielnik, Adam Włodarczyk, Wiesław Jerzy Cubała et al.
5 citations
Repeated series of intravenous ketamine infusions, given as an add-on treatment, can be effective and safe for patients with treatment-resistant depression. In a case series of five inpatients aged 43–63 with major depressive disorder or bipolar I disorder, four achieved remission after the first series of eight infusions, and three after the second series. Adverse reactions were mild and transient. The results are limited to short-term, add-on intravenous ketamine and cannot be generalized to long-term maintenance or other formulations.
Pharmaceuticals
May 3, 2021
Natalia Górska, Wiesław Jerzy Cubała, Jakub Słupski et al.
2 citations
Magnesium levels in the blood change over the course of ketamine treatment for depression. In patients with major depressive disorder or bipolar disorder, serum magnesium concentration was significantly higher before treatment began than after five or seven ketamine infusions. However, changes in magnesium levels were not correlated with depression scores on the Montgomery-Åsberg Depression Rating Scale (MADRS) or with mania scores on the Young Mania Rating Scale (YMRS). The study also found no link between magnesium concentration and somatic comorbidities. While the findings support the idea that magnesium plays a role in treatment-resistant depression, especially with ketamine, there is no clear evidence of a straightforward relationship between magnesium levels and treatment response or other health conditions.
Magnesium research
Jakub Słupski, Adam Włodarczyk, Natalia Górska et al.
Impulsive behaviors are common in major depressive disorder and bipolar disorder, raising suicide risk and mood instability. Ketamine, an NMDA receptor antagonist, can produce rapid antidepressant and antisuicidal effects, and magnesium given with low-dose NMDA antagonists reduces anxiety- and depression-like behaviors in animals. This observational study of 49 inpatients with treatment-resistant mood disorders measured impulsivity with the Barratt Impulsiveness Scale (BIS-11) and magnesium levels before and during a four-week course of eight ketamine infusions. Magnesium ion concentration during treatment was not associated with changes in BIS-11 scores. The findings provide no evidence for a relationship between magnesium levels and impulsivity during ketamine therapy.